Sort
4,870 grants matching “glp 1”
Gastric Endocrine Functions in Skeletal Homeostasis
$2,608,068Ziru Li · Mainehealth · R01 · FY2025 · DK
Developing autologous iPSC-RPE based IND for AMD patients
$2,586,989Kapil Bharti · National Eye Institute · ZIA · FY2022 · EY
Targeted Bone Regeneration via Activation of Resident Stem Cells
$2,585,805Sharie Haugabook · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR
Evaluation of Optimized Lead Candidates for Encephalitic Alphaviruses in Animal Models
$2,565,790Colleen B Jonsson · University Of Tennessee Health Sci Ctr · U19 · FY2021 · AI
Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man
$2,557,628Patricia Sue Grigson · Pennsylvania State Univ Hershey Med Ctr · UG3 · FY2020 · DA
An ultra-long-acting oral treatment for opioid use disorder
$2,543,976Andrew Martin Bellinger · Lyndra Therapeutics, Inc. · UG3 · FY2018 · DA
BSL-4 Evaluation Core (Core B)
$2,542,134Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2021 · AI
Core C - The University of Texas Medical Branch at Galveston
$2,538,747Thomas William Geisbert · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2023 · AI
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,535,440Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2022 · DA
Preclinical drug development in pancreatic cancer
$2,528,211Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
A Single Ascending Dose / Multiple Ascending Dose Phase I study of the GSM 776890 in healthy normal subjects
$2,522,029Douglas R Galasko · University Of California, San Diego · R01 · FY2022 · AG
The Global Land Programme (GLP): A key global research network of the Future Earth Initiative for Global Sustainability
$2,515,744Ariane C De Bremond · University Of Maryland, College Park · · FY2023 · GEO
Thin, High-Density, High-Performance, Depth and Surface Microelectrodes for Diagnosis and Treatment of Epilepsy
$2,500,069Shadi Dayeh · University Of California, San Diego · UG3 · FY2022 · NS
Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study
$2,499,231John M Lachin · George Washington University · U01 · FY2017 · DK
Fluorescence guided nerve sparing during colorectal cancer surgery using local application of a near infrared nerve fluorophore
$2,491,138Summer Lynne Gibbs · Oregon Health & Science University · R01 · FY2025 · CA
Regional Biocontainment Laboratory
$2,475,000Charles L Bailey · George Mason University · UC6 · FY2007 · AI
Molecular Mechanisms of Physiologic Beta Cell Growth in Juvenile Human Pancreas
$2,468,076Alvin Carter Powers · Vanderbilt University Medical Center · UC4 · FY2014 · DK
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,465,296Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2024 · DA
Protective Mechanisms In Cerebral Ischemia
$2,431,459John Hallenbeck · National Institute Of Neurological Disorders And Stroke · ZIA · FY2014 · NS
Optimization of Iron Chelator Delivery System
$2,425,024Judith K Gwathmey · Gwathmey, Inc. · R44 · FY2008 · HL
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).
$2,409,283David G Brooks · Boston Immune Technologies And Therapeutics, Inc. · R44 · FY2025 · CA
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
$2,380,269Lawrence R Toll · Phoenix Pharmalabs, Inc. · U01 · FY2023 · DA
CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease
$2,375,985Jan Johansson · Artery Therapeutics, Inc. · R44 · FY2020 · AG
Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man
$2,367,195Patricia Sue Grigson · Pennsylvania State Univ Hershey Med Ctr · UG3 · FY2019 · DA
Thin, High-Density, High-Performance, Depth and Surface Microelectrodes for Diagnosis and Treatment of Epilepsy
$2,364,802Shadi Dayeh · University Of California, San Diego · UG3 · FY2021 · NS